Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Yes, I’ve become that person: I exercise at least five times a week ... This means that gaining weight after treating weight loss, whether that loss came via Ozempic, Mounjaro, bariatric ...

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical ... giant that makes Ozempic and Wegovy, used a submission to the ...

Other experts agree. “When I’m helping patients find a plan for weight loss, I’m not saying, ‘Hey, let’s try this for 10 weeks and then switch,’” says Fatima Cody Stanford ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...